Riferimento:
Am J Hematol. 2012 Jun;87(6):596-603.
Autori:
Choudhry A, DeLoughery TG.
Fonte:
Am J Hematol. 2012 Jun;87(6):596-603.
Anno:
2012
Azione:
Trombosi ed alta incidenza di decessi per emorragie precoci sono ormai sempre più riconosciute nella leucemia promielocitica acuta (APL) e possono essere associate all'utilizzo dell'acido all-trans retinoico (ATRA).
Target:
ATRA/leucemia promielocitica acuta.
ABSTRACT
Acute promyelocytic leukemia (APL) has evolved from being a deadly to a highly curable disease, due to targeted molecular therapy with all-trans retinoic acid (ATRA). As a result, the incidence of early hemorrhagic deaths for which APL is notorious has reduced to 5-10% as reported in clinical trials. These results are not replicated outside of clinical trials as is evident from recent population-based registries. High incidence of early hemorrhagic deaths remains the greatest contributor to treatment failure in this otherwise curable leukemia. Additionally, thrombosis is now being increasingly recognized in APL patients and may be associated with ATRA usage.
Acute promyelocytic leukemia (APL) has evolved from being a deadly to a highly curable disease, due to targeted molecular therapy with all-trans retinoic acid (ATRA). As a result, the incidence of early hemorrhagic deaths for which APL is notorious has reduced to 5-10% as reported in clinical trials. These results are not replicated outside of clinical trials as is evident from recent population-based registries. High incidence of early hemorrhagic deaths remains the greatest contributor to treatment failure in this otherwise curable leukemia. Additionally, thrombosis is now being increasingly recognized in APL patients and may be associated with ATRA usage.
Sostanze: